Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
02 June 2021 - 6:31AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer Pursuant to Rule 13a-16
or 15d-16
Under the Securities Exchange Act of 1934
For the Month of June 2021
001-36203
(Commission File Number)
CAN-FITE BIOPHARMA LTD.
(Exact name of Registrant as specified in its charter)
10 Bareket Street
Kiryat Matalon, P.O. Box 7537
Petach-Tikva 4951778, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F þ Form 40-F ☐
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
This Report on Form 6-K (including exhibits
thereto) is hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File No. 333-227753)
and Form F-3 (File Nos. 333-195124, 333-236064, and 333-249063), to be a part thereof from the date on which this report is
submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
On June 1, 2021, Can-Fite BioPharma Ltd. (the
“Company”) announced that it postponed its annual general meeting of shareholders (the “Annual General Meeting”),
which was scheduled for May 31, 2021. Accordingly, the Company’s Annual General Meeting will be reconvened on Monday, June 7, 2021
at 3:00 p.m., Israel time at the Company’s offices located at 10 Bareket Street, Petach Tikva, Israel. In connection with the meeting,
the Company furnishes the following documents:
|
1.
|
A
copy of the Notice and Proxy Statement with respect to the Company’s Special Meeting of Shareholders describing the proposal to
be voted upon at the meeting, the procedure for voting in person or by proxy at the meeting and various other details related to the
meeting, attached hereto as Exhibit 99.1;
|
|
2.
|
A
form of Proxy Card whereby holders of ordinary shares of the Company may vote at the meeting without attending in person, attached hereto
as Exhibit 99.2; and
|
|
3.
|
A
form of Voting Instruction Card whereby holders of American Depositary Shares of the Company may vote at the meeting without attending
in person, attached hereto as Exhibit 99.3.
|
Exhibit Index
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
Date: June 1, 2021
|
By:
|
/s/ Pnina Fishman
|
|
|
Pnina Fishman
|
|
|
Chief Executive Officer
|
3
Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From Apr 2024 to May 2024
Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From May 2023 to May 2024